Search

Displaying results 731 - 740 of 10000 in total
  1. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019. … [L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872]

  2. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    in high risk adolescents and adults. … [L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

    Mixtures: EMTRICITABINA E TENOFOVIR DISOPROXIL EG, EMTRICITABINA E TENOFOVIR DISOPROXIL EGCategories: Antivirals used in combination for the treatment of HIV infections
  3. Drug

    Benzylpenicillin

    go.drugbank.com/drugs/DB01053
    ApprovedInvestigationalVet approved

    The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix … Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.

    Mixtures: BENZAPEN 6.3.3 IM ENJ TOZ ICEREN FLAKON, 1 ADET, BENZAPEN 6.3.3 IM ENJ TOZ ICEREN FLAKON, 1 ADETProducts: Novo-pen G 500
  4. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth

  5. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents. … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  6. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

  7. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients … The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].

    Synonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinateCategories: Receptors, Prostaglandin E, EP2 Subtype, agonists
  8. Drug

    Sodium acetate

    go.drugbank.com/drugs/DB09395
    ApprovedInvestigational

    Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. … It can be used also in metabolic acidosis and for urine alkalinization.

    Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 ML
  9. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … on further verification in confirmatory trials.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    a range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development